Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|January 6, 2014
New Multiple Sclerosis Publication Available
Current Topics in Multiple Sclerosis features review articles on the diagnosis and treatment of multiple sclerosis.
Advertisement
Current Topics in Multiple Sclerosis features review articles on the diagnosis and treatment of multiple sclerosis.
The American Journal of Managed Care has published a new supplement, Current Topics in Multiple Sclerosis. The supplement features review articles on the impact of early diagnosis and treatment of multiple sclerosis (MS), the selection process for disease-modifying treatments, and new and emerging therapies for relapsing-remitting MS.
To access Current Topics in Multiple Sclerosis, follow this
Advertisement
Related to this article
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5